BNP Paribas Financial Markets’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.25M | Sell |
381,856
-42,215
| -10% | -$912K | ﹤0.01% | 1681 |
|
|
2025
Q4 | $10.1M | Buy |
424,071
+340,048
| +405% | +$6.94M | ﹤0.01% | 1609 |
|
|
2025
Q3 | $1.14M | Buy |
84,023
+77,433
| +1,175% | +$805K | ﹤0.01% | 3034 |
|
|
2025
Q2 | $53.6K | Sell |
6,590
-810
| -11% | -$6.92K | ﹤0.01% | 4237 |
|
|
2025
Q1 | $58.1K | Sell |
7,400
-12,941
| -64% | -$150K | ﹤0.01% | 4237 |
|
|
2024
Q4 | $303K | Buy |
20,341
+9,016
| +80% | +$147K | ﹤0.01% | 3625 |
|
|
2024
Q3 | $173K | Sell |
11,325
-9,827
| -46% | -$155K | ﹤0.01% | 3303 |
|
|
2024
Q2 | $322K | Sell |
21,152
-14,488
| -41% | -$234K | ﹤0.01% | 2880 |
|
|
2024
Q1 | $673K | Sell |
35,640
-74,726
| -68% | -$1.29M | ﹤0.01% | 2689 |
|
|
2023
Q4 | $2.11M | Buy |
110,366
+27,048
| +32% | +$432K | ﹤0.01% | 1925 |
|
|
2023
Q3 | $1.5M | Buy |
83,318
+20,533
| +33% | +$413K | ﹤0.01% | 2060 |
|
|
2023
Q2 | $1.28M | Sell |
62,785
-100,511
| -62% | -$1.91M | ﹤0.01% | 2044 |
|
|
2023
Q1 | $2.98M | Buy |
163,296
+118,769
| +267% | +$2.27M | ﹤0.01% | 1556 |
|
|
2022
Q4 | $921K | Sell |
44,527
-92,430
| -67% | -$2.54M | ﹤0.01% | 2212 |
|
|
2022
Q3 | $3.58M | Buy |
136,957
+73,204
| +115% | +$1.94M | 0.01% | 1548 |
|
|
2022
Q2 | $1.62M | Buy |
63,753
+53,291
| +509% | +$1.31M | ﹤0.01% | 1896 |
|
|
2022
Q1 | $330K | Sell |
10,462
-6,789
| -39% | -$227K | ﹤0.01% | 2951 |
|
|
2021
Q4 | $698K | Buy |
17,251
+5,686
| +49% | +$221K | ﹤0.01% | 2826 |
|
|
2021
Q3 | $403K | Buy |
11,565
+5,879
| +103% | +$183K | ﹤0.01% | 2828 |
|
|
2021
Q2 | $156K | Buy |
5,686
+74
| +1% | +$2.11K | ﹤0.01% | 2924 |
|
|
2021
Q1 | $158K | Sell |
5,612
-554
| -9% | -$19.3K | ﹤0.01% | 3146 |
|
|
2020
Q4 | $160K | Sell |
6,166
-4,770
| -44% | -$115K | ﹤0.01% | 2986 |
|
|
2020
Q3 | $187K | Buy |
10,936
+7,483
| +217% | +$167K | ﹤0.01% | 2785 |
|
|
2020
Q2 | $85.4K | Sell |
3,453
-6,574
| -66% | -$177K | ﹤0.01% | 2831 |
|
|
2020
Q1 | $139K | Buy |
10,027
+2,139
| +27% | +$26.6K | ﹤0.01% | 3047 |
|
|
2019
Q4 | $79.7K | Buy |
7,888
+2,857
| +57% | +$24K | ﹤0.01% | 3388 |
|
|
2019
Q3 | $45.8K | Sell |
5,031
-120
| -2% | -$964 | ﹤0.01% | 3527 |
|
|
2019
Q2 | $41K | Sell |
5,151
-1,370
| -21% | -$13.7K | ﹤0.01% | 3542 |
|
|
2019
Q1 | $81.4K | Buy |
6,521
+6,200
| +1,931% | +$67.3K | ﹤0.01% | 3245 |
|
|
2018
Q4 | $3.46K | Buy |
321
+152
| +90% | +$1.77K | ﹤0.01% | 3693 |
|
|
2018
Q3 | $2.36K | Sell |
169
-1
| -0.6% | -$13 | ﹤0.01% | 4236 |
|
|
2018
Q2 | $2.08K | Buy |
+170
| New | +$2.67K | ﹤0.01% | 4248 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
BNP Paribas Financial Markets's RCUS Position: Q1 2026 in Review
BNP Paribas Financial Markets reduced its Arcus Biosciences (RCUS) stake by 10% in Q1 2026, selling an estimated $912K and leaving 381,856 shares worth $8.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1681.
BNP Paribas Financial Markets first reported a position in RCUS in Q2 2018 and has held it in 32 quarters since. The position peaked at $10.1M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- BNP Paribas Financial Markets held 381,856 shares of Arcus Biosciences worth $8.25M as of Q1 2026.
- BNP Paribas Financial Markets sold 42,215 Arcus Biosciences shares in Q1 2026, an estimated $912K.
- Arcus Biosciences made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #1681 holding.
- BNP Paribas Financial Markets first reported a position in Arcus Biosciences in Q2 2018 and has held it in 32 quarters since.
- BNP Paribas Financial Markets's Arcus Biosciences position peaked at $10.1M in Q4 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.